Showing 1 - 20 results of 46,043 for search '(((( _ fold decrease ) OR ( 2 mg decrease ))) OR ( 50 ((a decrease) OR (_ decrease)) ))*', query time: 1.03s Refine Results
  1. 1
  2. 2

    Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

    Published 2016
    “…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
  3. 3
  4. 4

    The rate of lariat formation is decreased two-fold by isoginkgetin treatment. by Jesse M. Gray (527662)

    Published 2014
    “…(<b>C</b>) Isoginkgetin treatment leads to a decreased rate of lariat formation (* indicates <i>p</i> = 0.02) without affecting exon ligation or excised lariat degradation (<i>p</i> = 0.22, 0.08), with calculations as in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0089673#pone-0089673-g001" target="_blank">Fig. 1</a>. …”
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11

    FTY720 treatment decreased tumor growth in a xenograft model of hepatoblastoma. by Laura L. Stafman (6577184)

    Published 2019
    “…<p>(A) HuH6 cells (2.5 x 10<sup>6</sup> cells in 25% Matrigel) were injected subcutaneously into the right flank of 6-week-old female athymic nude mice. …”
  12. 12
  13. 13

    Relationship between Differential Hepatic microRNA Expression and Decreased Hepatic Cytochrome P450 3A Activity in Cirrhosis by Raj Vuppalanchi (458660)

    Published 2013
    “…Notably, miR-155, a known regulator of liver inflammation, had the highest fold increase in cirrhotic livers (2.2-fold, P=4.16E-08) and significantly correlated with hepatic CYP3A activity (r=-0.50, P=0.017). …”
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19

    Belinostat decreases both male and female bladder weights in transgenic superficial bladder cancer mice by Michael T Buckley (37161)

    Published 2011
    “…Normal non-transgenic mouse bladders weigh approximately 10.0 mg at the same age, and Ha-transgenic mice with superficial bladder cancer have a 3 fold and higher bladder weight. , Male belinostat-treated mice (n = 4, 327.5 mg average weight) showed a two-fold decrease (50%, p = 0.03) in bladder weight versus control (n = 4, 652.5 mg average weight). , Female belinostat-treated mice (n = 5, 34.0 mg average weight) showed a 36% decrease (p = 0.04) in bladder weight versus control (n = 6, 53.3 mg average weight).…”
  20. 20